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 ABSTRACT 
 
Kankkunen, T., 2002. Controlled transdermal drug delivery by iontophoresis and ion-
exchange fiber. 
 
Dissertationes Biocentri Viikki Universitatis Helsingiensis 17/2002, pp. 57 
ISBN 952-10-0313-8 (print) ISBN 952-10-0314-6 (pdf) ISSN 1239-9469 
 
A common aim in the development of new transdermal devices is the controlled delivery 
of drugs, so that the rate of drug input into the blood stream is predictable and reproducible. The 
transdermal therapeutic systems act as drug reservoirs and control the penetration rate of the drug 
into the skin and subsequent permeation into the blood circulation. Obviously, the release of the 
drug from the device can be controlled more exactly than the permeability of drugs in the skin. 
The outermost layer of the skin, stratum corneum, is usually the rate-limiting step in the 
permeation of drugs through the skin. Passive permeability of drugs across this layer is especially 
difficult to compounds which are hydrophilic, very lipophilic, of high molecular weight or 
charged. Iontophoresis is a process, by which the transport of ions into and through the skin is 
increased by the application of an external electric field across the skin.  
One alternative to achieve controlled transdermal drug delivery is binding the drug into 
an ion-exchange fiber. Ion-exchange fibers consist of a polymeric framework, into which the 
ionic groups (e.g. –COO-, NH3+) are bound. Controlled drug delivery by the ion-exchanger may 
be achieved by manipulating the properties of drug, ion-exchanger and/or external solution in the 
device. 
In the present study, the effects of drug properties (six model drugs), fiber properties (six 
anion- and cation-exchange fibers), and medium properties (ionic strength, pH, volume, salt 
choice) on the drug binding into and drug release from the fibers were determined. Drug release 
from the fibers, with and without iontophoresis, and fluxes of the drugs across human stratum 
corneum were investigated in vitro. Drug stability in the ion-exchange fiber formulations was 
studied as well. Iontophoretic delivery of tacrine from a solution formulation and an ion-exchange 
fiber formulation was compared in vivo in healthy human volunteers. Finally, permeation of 
tacrine in vitro was compared to the in vivo results. 
The binding and release of drugs into/from the ion-exchange fibers depends on a specific 
combination of the drug, fiber, and the concentration and nature of the external electrolyte. The 
distribution equilibrium of the drug is affected by drug-fiber interactions, which are specific to 
the ion-exchange group and the fiber nature. In vitro permeation of tacrine across the skin was 
directly related to the iontophoretic current density and to the drug concentration used. As the 
drug has to be released from the ion-exchanger before permeating across the skin, a clear 
reduction in the drug fluxes from the ion-exchange fibers were observed as compared to the 
corresponding fluxes of the drugs from solution. Ion-exchange fiber also improved the stability of 
easily oxidised levodopa during storage in water. Iontophoretic current and ion-exchange fiber 
may be used to control tacrine permeation across the skin and to achieve clinically relevant 
plasma concentrations with minor irritation on the skin. The in vitro and in vivo correlation of 
tacrine permeation was dependent on the experimental conditions and device structure.  
 In conclusion, cation- and anion-exchange fibers were shown to be promising materials 
to form a drug reservoir and to control the drug release from an iontophoretic transdermal system. 
By optimal selection of the external conditions (ionic-strength, pH, and salt), the drug properties 
(charge, lipophilicity, molecular weight), and the fiber quality (ion-exchange groups, capacity), 
one could achieve controlled release kinetics of a drug from the ion-exchange fiber and, 
subsequently, controlled transdermal drug permeation. 
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1 INTRODUCTION 
 
Transdermal drug delivery is an alternative route for systemic drug delivery. It offers 
many important advantages over oral drug delivery, e.g., avoids gastrointestinal tract and 
hepatic first-pass biotransformation and metabolism, controls absorption rate, increases 
patient compliance, and enables fast termination of drug delivery if needed (Singh and 
Maibach, 1994; Sathyan et al., 1995; Berti and Lipsky, 1995). A common aim in the 
development of new transdermal devices is the controlled delivery of drugs, so that the 
rate of drug input into the blood stream is predictable and reproducible. The transdermal 
therapeutic systems act as drug reservoirs and control the penetration rate of the drug into 
the skin and subsequent drug permeation into the blood circulation. When the device 
controls the transdermal drug flux instead of the skin, delivery of the drug is more 
reproducible leading to smaller inter- and intrasubject variations. Obviously, release of 
the drug from the device can be controlled more exactly than the permeability of drugs 
across the skin (Guy and Hadgraft, 1992). The permeability barrier of the skin changes 
with age and anatomical site (Bach and Lippold, 1998) and, therefore, the problem of 
variable in vivo drug absorption is common in both the passive and iontophoretic drug 
delivery, and this restricts the use of transdermal therapeutic systems (Guy and Hadgraft, 
1992; Fiset et al., 1995). 
 
One alternative to achieve controlled transdermal drug delivery is binding of the drug 
into an ion-exchange fiber (Hänninen et al., 2001). Charged drugs are bound into the ion-
exchange groups until released by mobile coions. Complexation of drugs with ion-
exchange resins has been studied as a promising means of achieving controlled drug 
release (Conaghey et al., 1998a; 1998b), enhanced drug stability (Jani et al., 1994; 
Conaghey et al., 1998a) and drug delivery (Irwin et al., 1990). Selection of 1) external 
conditions (e.g., ionic-strength, pH, and choice of salt in the release solution), 2) drug 
properties (charge, lipophilicity and molecular weight) and 3) fiber quality (ion-exchange 
groups, capacity), affect the release kinetics of a drug from ion-exchange systems. 
Conaghey et al. (1998a; 1998b) used a hydrogel containing ion-exchange resins to 
transport nicotine across the skin. They observed that binding of nicotine into the ion-
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exchange resins makes the gel formulations unsuitable for passive transdermal drug 
delivery. However, iontophoretic current was observed to enhance the rate of nicotine 
delivery from the ion-exchange resins considerably (Conaghey et al., 1998b). As with 
resins, the major interest in the use of ion-exchange fibers in formulation development is 
to provide a controlled drug adsorption/binding into the fiber and to create a stable drug 
reservoir during storage. A controlled release profile and predetermined drug absorption 
from the transdermal drug delivery system may then be attempted by optimizing the 
properties of the ion-exchange fiber(s) and electrical current (iontophoresis).  
 
The specific objectives of this work were to study the properties and utilization of ion-
exchange fibers in controlled transdermal drug delivery, and to determine, whether 
therapeutically relevant plasma concentrations of a model drug, tacrine, could be 
achieved using iontophoretic transdermal drug delivery in healthy human volunteers. 
 
2 REVIEW OF LITERATURE 
 
2.1 Transdermal drug delivery 
 
Transdermal drug delivery systems have been existing for a long time. In spite of major 
research and development efforts in transdermal systems and the many advantages of the 
transdermal route, there still are some problems that limit the clinical use of the 
transdermal approach. The disadvantages of transdermal systems are, that drugs, which 
require high-blood levels can not been administered, drug or drug formulation may cause 
skin irritation or sensitization, it may be uncomfortable to use, and the system is not 
economical (Guy and Hadgraft, 1989; Ranade, 1991; Berti and Lipsky, 1995). The 
transport of drugs through the skin is complex since many factors influence their 
permeation. These factors are 1) skin structure and its properties, 2) the penetrating 
molecule and its physico-chemical properties, 3) delivery system carrying the penetrant, 
and 4) the combination of skin, the penetrating molecule and the delivery system 
(Ranade, 1991). Benefits of transdermal drug delivery include bypass of the hepatic first 
pass effect and gastrointestinal side effects, controlled plasma levels of potent drugs with 
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short biological half-lives, increased patient compliance, allowed administration of drugs 
with narrow therapeutic window, and ease of terminating drug delivery if toxicities occur. 
This noninvasive drug delivery system also minimizes trauma, risk of infection, damage 
to the wound, and it is an important alternative to parenteral infusion (Singh and 
Maibach, 1994; Ranade, 1991; Berner and John, 1994). 
  
The skin is a multilayered organ that is complex in both the structure and function 
(Walters, 1989). At physiological pH human skin has a net negative charge (Burnette, 
1988). The skin is composed of the epidermis, dermis, and underlying subdermal tissue. 
The epidermis is composed of five layers of cell types, beginning from the skin surface: 
stratum corneum, stratum lucidum, stratum granulosum, stratum spinosum, and stratum 
basale (Berti and Lipsky, 1995). The major barrier to drug penetration and permeation in 
the skin is the stratum corneum, a dead layer of tissues. The majority of human stratum 
corneum lipids consist of ceramides and neutral lipids such as free sterols, free fatty 
acids, and triglycerides. Structure of the stratum corneum is that of a rigidly arranged and 
lipophilic membrane, which forms the most impermeable membrane in humans (Guy and 
Hadgraft, 1989). There is no active transport across the skin (Hadgraft, 1996). The 
stratum corneum offers three possible routes of drug permeation, transcellular (through 
cells), intercellular (between cells) and appendageal (via the sweat glands, hair follicles 
and sebaceous glands) pathways (Cullander, 1992; Prausnitz, 1996a). Small (MW < 400 
g/mol) lipophilic (log Poct 2-3) molecules permeate passively mostly by the intercellular 
path between the corneocytes. Also the passive flow of charged and polar molecules 
occurs dominantly via the intercellular pathway. Iontophoretic flow of large, hydrophilic 
and charged molecules occurs mainly through the skin appendages (Cullander, 1992; 
Turner and Guy, 1997). Since appendages make up a very small percentage of the total 
skin surface (about 0.1 %), ion transport may also occur via the intercellular path in both 
the passive and iontophoretic transport (Singh et al., 1998).   
 
Transdermal drug delivery can be described in three principal stages: 1) delivery of the 
molecule to the skin surface, 2) passage of the molecule through the skin, and 3) 
distribution of the molecule into the site of action via the systemic circulation. Either step 
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1 or 2 is the permeation rate limiting step. In the passive delivery the transport of the 
molecule across the stratum corneum is the rate limiting factor. Controlled transdermal 
delivery systems are developed so that the diffusion of drug in the polymer membrane of 
the product is the rate limiting step (Guy and Hadgraft, 1992; Berti and Lipsky, 1995; 
Wang et al., 1998; Ocak and Ağabeyoğlu, 1999). Controlled drug delivery is generally 
achieved by manipulating the properties of drugs and/or drug delivery devices or carriers. 
When the device controls the transdermal drug flux instead of the skin, delivery of the 
drug is, presumably, more reproducible. 
 
2.2 Enhancement of transdermal permeation 
 
2.2.1 General aspects 
 
Many of the drugs under study have not any great abilities to cross the skin, and ways 
must be found to modify the diffusional barrier or to increase drug permeation by another 
way (Walters, 1989). Passive permeation across the stratum corneum is especially 
difficult to compounds which are hydrophilic (log Poct < 1), very lipophilic (log Poct > 3), 
of high molecular weight (MW > 400 g/mol) or charged. Generally, methods to enhance 
transdermal drug permeation can be grouped into two categories: chemical methods and 
physical methods. Chemical enhancers and prodrugs have been found to increase 
transdermal drug transport via several different mechanisms, including increased 
solubility of the drug in the donor formulation, increased drug partitioning into the 
stratum corneum, fluidization of the lipid bilayers, and disruption of the intracellular 
proteins (Barry, 1987; Aungst et al., 1990; Rautio et al., 1998). It is obvious that many 
different groups of chemicals have the potential to alter the barrier properties of skin 
(Walters, 1989; Suhonen et al., 1999). Many of the chemical enhancers are irritants and, 
therefore, methods which are safe and effective are under development. The prodrugs are 
pharmacologically inactive drug molecules, which require a chemical or enzymatic 
transformation to release the active parent molecule (Rautio et al., 1998). Prodrugs have 
been used to improve the delivery of drug across the skin, because a lot of nonspecific 
esterases and other enzymatic activity are present in the epidermis. However, high 
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prodrug concentration in the skin may lead to enzyme saturation, which hinders the 
conversion of a prodrug into an active drug molecule.   
 
In order to control the drug delivery across the skin more precisely, physical methods 
have been tested to create effective transdermal drug delivery (Bellantone et al., 1986; 
Rolf, 1988; Burnette, 1988; Prausnitz et al., 1996b; Mitragotri, 2001; Lin et al., 2001). 
Phonophoresis or sonophoresis refers to the use of (low-frequency) ultrasound for 
enhancing percutaneous absorption of various therapeutic agents. Iontophoresis and 
electroporation use electrical current/voltage to deliver charged or uncharged molecules 
into the skin (Rolf, 1988). Electroporation involves the creation of transient aqueous 
pathways in the lipid bilayer membrane by the application of a short electric field pulse 
(Prausnitz, 1998). Two main pulse protocols have been employed to promote transport; 
intermittent application of short high-voltage pulses (about 1 ms and 100 V across the 
skin) and a few applications of long medium-voltage pulses (about 100 ms and > 30 V 
across the skin) (Vanbever et al., 1999). Iontophoresis is a process in which the transport 
of ions into or through the skin is increased by the application of an external electric field 
across the human skin. The constant current density used is 0.5 mA/cm2 at maximum (no 
unbearable pain or prolonged skin irritation) (Ledger, 1992). Iontophoresis uses the 
potential difference between two electrodes to transport solutes. The use of iontophoretic 
current has been shown to enhance significantly the rate of drug delivery from a 
transdermal device over the corresponding passive transport (Burnette, 1988). The 
mechanisms of iontophoresis and electroporation appear to be completely different. In 
iontophoresis the flux is related to the total charge transported through the system, while 
electroporative voltage pulses produce transient permeabilization of the stratum corneum, 
and the transport can not be related to the amount of charge passed across the skin 
(Bommannan et al., 1994; Prausnitz, 1998). The interest in the physical enhancement 
methods has increased as a potential way to deliver noninvasively new drugs that have 
been produced by novel biotechnological methods (peptides, oligonucleotides, genes) 
(Table 1).  
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Table 1. Methods to enhance transdermal permeability of (macromolecular) 
drugs. Methods are more or less in the order of increasing invasiveness 
(modified from Hirvonen and Jaskari, 2001). 
 
Method     Mode of action 
 
Chemical enhancers Compromisation of the tightly structured stratum corneum 
lipid bilayers  
 
Lipid vesicles   Cumulation of drugs in the stratum corneum 
 
Iontophoresis Low current/voltage electrostatic repulsion, electroosmosis 
 
Low-frequency ultrasound Local thermal effect, weakened bilayers of the stratum 
corneum by cavitation 
 
Electroporation High voltage short term electrical pulses 
 
(Micro)needles Transient holes in the skin 
 
Pressurised He-gas Invasive “gene guns” 
 
 
 
2.2.2 Iontophoresis 
 
Iontophoresis enchances transdermal drug delivery by three mechanisms: 1) the 
electrorepulsion (migration), which enhances only the flux of charged molecules 
(Burnette, 1988; Peck et al., 1998), 2) the electroosmotic solvent flow, which enhances 
the flux of both charged and neutral molecules (Burnette, 1988; Pikal, 1992), and 3) the 
increased permeability of skin by the flow of electric current. The applied potential 
difference across the skin can lead to alterations in the tissue permeability, which, 
nonetheless, typically has no great significance (Sugar, 1979; Teissie and Tsong, 1981; 
Benz and Zimmerman, 1981; Glaser et al., 1988; Sims et al., 1991). Potential difference 
across the skin between two opposite sign electrodes causes electrorepulsion of ions 
through the skin (Fig. 1). Electrorepulsion takes place due to the repulsion between the 
electrode and drug of the same sign. It is the most important mechanism in the 
iontophoresis of small drug molecules (Burnette, 1988). The significance of 
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electrorepulsion and electroosmosis depends on the physico-chemical and electrical 
properties of the membrane, and of the permeant (Lu et al., 1993; Delgado-Charro and 
Guy, 1994; Hoogstraate et al., 1994; Hirvonen et al., 1996; Guy et al., 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The principle of iontophoresis. The vo
wall-like stratum corneum (SC) provides the pot
driving force of ions across the skin during the co
SC is a non-conductive lipophilic membrane a
hydrophilic epidermis and dermis (modified from G
 
 
Electroosmotic flow is bulk fluid flow, which occurs 
across a charged membrane. Electroosmotic flow is al
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Guy, 1996; Hirvonen et al., 1996; Hirvonen and Guy, 1997; Luzardo-Alvares et al., 1998; 
Marro et al., 2001).  The amount of electroosmotic flow has been predicted by theoretical 
models (e.g., limiting law analysis of electrical volume force, law of Manning (1967), 
Hildreth (1970), Gonzales-Tovar et al. (1991) and others (Pikal, 1990; 1992)). It has been 
demonstrated, that the electroosmotic flow can be modulated by the properties of 
permeant. It is generally accepted that the contribution of electroosmotic flux becomes 
greater, as compared to electrorepulsion, as the molecular size of an ion increases (Pikal, 
1992). Lipophilic, cationic drugs, e.g., LHRH-peptides and β-blocking agents, can evoke 
a dramatic effect on the permselective properties of human skin and on the extent and 
direction of the electroosmotic flow (Delgado-Charro et al., 1995; Hirvonen et al., 1996; 
Hirvonen and Guy, 1997). These lipophilic cations are able to become strongly associated 
with the net negative charge on the membrane, when iontophoresed at neutral pH 7.4 and, 
essentially, to stop completely the electroosmotic flow by neutralizing the charge of the 
skin membrane.  
 
2.3 Ion-exchange fibers 
 
2.3.1 General aspects 
 
Ion-exchange products have several applications in pharmacy for controlled or sustained 
drug delivery. Adams and Holmes synthesized the first ion-exchange resins in 1935 
(Adams and Holmes, 1935). From 1950′s to the present the complexation of drugs with 
ion-exchange resins has been studied extensively (Chaudhry and Saunders, 1956; Burge 
et al., 1986; Irwin et al., 1987; 1990; Jani et al., 1994; Conaghey et al., 1998a; 1998b). 
The advantage of ion-exchange materials for controlled drug delivery is their ability to 
bind and exchange charged drug molecules. Several peroral ion-exchange products have 
been developed for sustained and controlled drug release (Chaudhry and Saunders, 1956; 
Burge et al., 1986; Irwin et al., 1987; 1990). An ocular delivery system which utilizes 
ion-exchange resins has also been commercialized (Joshi, 1994). Nasal drug delivery 
systems based on ion-exchange resins (delivery of nicotine, vaccines, peptides, proteins 
and enzymes) have been patented (Illum, 1996; Mizushima et al., 1996). Conaghey et al. 
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(1998a; 1998b) have studied the use of ion-exchange resins in passive and iontophoretic 
transdermal drug delivery. The benefits of the properties of ion-exchange fiber, as 
compared for example to resins, are good mechanical strength and chemical inertness, 
easy handling, extensive surface, and the possibility of achieving a very high capacity (in 
other words, a high extent of grafting) (Sundell and Näsman, 1993). The backbone of the 
fiber (e.g., polyethylene, polypropylene) is grafted by radiation under an electron beam 
with a wanted substance (e.g., polyacrylic acid, polyamine, polystyrene) (Ekman, 1994; 
Sundell et al., 1995; Mäki-Arvela et al., 1999). Graft polymerization offers a number of 
different possibilities to control drug adsorption into the fiber to form a drug reservoir, 
and to control the drug release from this reservoir. The ion-exchange capacity increases 
with the increasing amount of ion-exchange groups in the polymeric backbone. 
Typically, only a low fraction of the drug in the ion-exchanger is released and available 
for transport into the place of clinical effect. The higher the capacity of the fiber the more 
drug molecules are available to be released and permeated across the skin. 
 
2.3.2 The structure 
 
The most important class of ion-exchangers is the organic ion-exchange resins (Fig. 2a). 
They consist of a framework, a so called matrix, carrying a positive or negative electric 
fixed charge, which is compensated by mobile counter ions of opposite sign. A small 
amount of mobile ions of the same sign (coions) can also be present. The framework is 
typically a hydrophobic hydrocarbon chain. Ionic groups in the framework are such as –
SO3-, -COO-, -PO32-, -AsO32- in cation-exchangers and –NH3+, -NH2+, -NH+ and –S+ in 
anion-exchangers (Helfferich, 1995). The structure of an ion-exchange fiber is generally 
the same as in resins, but the resins have crosslinked grafted side chains which the fibers 
do not have (Fig. 2b) (Ekman, 1994). Ion-exchange fibers are like a cloth, with an 
arranged structure. Because of non-crosslinked structure, high molecular weight 
biomolecules may fit better and be bound into the ion-exchange groups and, thereafter, 
may be delivered to the site of action. On the other hand, cross-linking of the resin may 
hinder the movement of a molecule and, therefore, hinder the drug release from the 
binding sites. 
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a) 
   
 
 
 
 
 
 
 
b) 
   
          
   
 
 
 
Figure 2. Schematic presentation of the structure of a) ion-exchange resin 
and b) ion-exchange fiber (modified from Ekman, 1994; Florence and 
Attwood, 1998). 
 
In the ion-exchange resins the ions are known to be bound to the ion-exchanger by two 
mechanisms. The first layer of molecules is bound strongly via electrostatic bonds. These 
strong bonds have a chemical nature and only ionized molecules are capable to be bound 
to this layer, where the concentration of binding molecules is very high. The molecules 
bind to the second layer via loose interactions of hydrophobic nature. The hydrophobic 
interactions may also occur between the side chains of bound molecules. Both the ionized 
and non-ionized molecules will be present in the second layer (Conaghey et al., 1998b; 
Marchal-Heussler et al., 2000). 
 
The chemical nature of the ion-exchange groups greatly affects the equilibrium of ion-
exchange in the fiber. An important factor is the acid and base strengths of the active 
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groups. Weak acidic groups, such as –COO-, are ionized only at a high pH. In contrast, 
strong acidic groups, e.g. -SO3-, are ionized even at a low pH. The physico-chemical 
properties of drugs and binding/dissolution medium affect also to the binding and 
releasing kinetics.   
 
2.3.3 Theory of ion-exchange 
 
Ion-exchange is a stoichiometric process in which any counter ions that leave the ion-
exchanger are replaced by an equivalent amount of other counter ions (Fig. 3) 
(Raghunathan et al., 1981). This is a consequence of the electroneutrality requirement. 
The ion-exchange is essentially a diffusional process, but also has relation to chemical 
reaction kinetics. Usually the ion-exchangers are selective, they take up some counter 
ions in preference to others. The rate-determining step in ion-exchange is diffusion either 
within the ion-exchanger itself or in the diffusion boundary layer (Helfferich, 1995). 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The principle of drug binding into the ion-exchange fiber and 
drug release from the fiber (modified from Åkerman, 1999).  
  COOH COOH 
Activation e.g. in 
NaCl/NaOH 
solution   
COO-Na+ COO-Na+ 
Fiber discs in 
drug solution 
   COO-drug+ COO-drug+ 
Fiber discs in 
releasing solution   
e.g. in NaCl 
   COO-Na+ COO-Na+ 
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The equilibrium distribution of the drug species between the fiber and external solution 
phases results from both electrostatic and hydrophobic interactions. The former are 
measured by the electrical partition coefficient (Ke,d) (Helfferich, 1995) 
 , exp( / )e d d DK z F RTφ= −                              (Equation 1), 
where F, R, and T are the Faraday constant, the gas constant, and the absolute 
temperature, respectively, and Dφ φ φ≡ −  (i.e., the electrical potential in the ion-
exchanger  (overbar) with respect to the external phase) is the Donnan potential, which is 
determined by the ion-exchange capacity of the ion-exchanger and the nature and 
concentration of the external solution. In the case of cationic drugs (charge number 
zd > 0) in cation-exchange membranes, φD is negative and Ke,d  > 1. Similarly, the 
chemical partition coefficient (Kc,d) (Lyklema, 1991)  
                                 
00
, exp[( ) / ]c d d dK RTµ µ= −                        (Equation 2), 
measures the tendency of the drug to get into the ion-exchanger as a result of the specific 
interaction of the drug with the hydrophobic ion-exchanger. In Eq. (2), 0dµ  is the standard 
chemical potential of the drug species, and overbars denote the ion-exchanger phase. The 
more hydrophobic the drug, the larger the decrease in free energy associated to its 
interaction with the ion-exchanger and the larger the value of Kc,d (> 1). In the case of 
hydrophilic drugs, however, Kc,d could be smaller than one. (The water content of the 
ion-exchanger also affects the value of Kc,d). Finally, the molar drug concentration ratio 
is (Laksminarayanaiah, 1984) 
                                      , , ,
d
d
p d e d c d
c K K K
c
= =                           (Equation 3), 
which results from the fact that the electrochemical potential of the drug species takes the 
same value in the ion-exchanger and external solution phases under equilibrium 
conditions (Donnan equilibrium).  
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2.3.4 Characterization of drug delivery systems based on ion-exchange 
  
Using an ion-exchanger and iontophoresis one may presumably achieve controlled 
transdermal drug delivery. The most commonly used methods to control iontophoretic 
drug delivery across the skin are current density and donor drug concentration, both of 
which are directly related to the drug flux (Padmanabhan et al., 1990; Miller et al., 1990). 
Despite the relative attenuation in the extent of maximal drug delivery, additional and 
more precise control of transdermal iontophoresis is expected to be achieved by ion-
exchange approach (Conaghey et al., 1998b). By changing the external conditions one 
may affect the drug release, but also the properties of the drug and ion-exchanger have an 
important role in the drug adsorption and drug release (Irwin et al., 1990; Jenquin et al., 
1990; Conaghey et al., 1998a; 1998b; Åkerman et al., 1999).  
 
Different drug adsorption methods have been developed to determine the amount of drug 
molecules in the ion-exchanger and the degree of ion-exchange in the pharmaceutical 
products (Benoit et al., 1994; Prot et al., 1996; Conaghey et al., 1998a; 1998b; Mäki-
Arvela et al., 1999; Marchal-Heussler et al., 2000). Using dielectric measurements 
(dielectric loss, dielectric permittivity) one may determine the electrical properties of the 
ion-exchanger, and by the use of adsorption isotherms the amount of a drug in the ion-
exchange material (Benoit et al., 1994; Prot et al., 1996; Marchal-Heussler et al., 2000). 
There are several different ways to determine the adsorption isotherm (Conaghey et al., 
1998a; 1998b; Mäki-Arvela et al., 1999). Despite the differences in these determinations, 
the basic idea is the same: drug adsorbed into the ion-exchanger = total drug – free drug. 
Summary of the properties of drug, ion-exchanger and external solution, which all affect 
the binding and release kinetics of a drug from the ion-exchange system, is presented in 
Table 2. 
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Table 2. Effects of the properties of drug, ion-exchanger and external solution 
on the binding of a drug into and release kinetics from the ion-exchange 
system. 
 
Property    Effect     Reference 
 
 
pKa of the drug   => charged sites of drug         Hänninen et al., 2001 
pH of the solution  => charged sites of drug and ion-exchanger       Charman et al., 1991 
Lipophilicity of the drug  => binding affinity         Hänninen et al., 2001 
Drug concentration in the    
ion-exchanger   => amount of drug release         Conaghey et al., 1998b 
Ion-exchange groups    
of the ion-exchanger  => binding affinity         Conaghey et al., 1998a  
 
Degree of grafting  => extent of drug release depending on  
      the properties of drug         Åkerman et al., 1998 
Particle size of the ion-exchanger => adsorption capacity 
    => drug release          Burge et al., 1986  
Ionic strength of the  
releasing solution   => drug release          Sawaya et al., 1988 
 
Medium of drug loading  => binding affinity  
=> drug release          Jenquin et al., 1990 
Salt choice   => affinity of salt molecule  
        to ion-exchange groups  
=> drug release          Charman et al., 1991 
Crosslinking the hydrocarbon   
network of the ion-exchange resin => drug release          Irwin et al., 1990 
Temperature of loading medium => drug incorporation         Chen et al., 1996 
 
Temperature of releasing medium => drug release          Irwin et al., 1990 
 
Stirring speed   => drug release          Chen et al., 1996 
     
 
Due to the properties of the ion-exchanger and the drugs (e.g., pKa), changes in the pH 
affect the binding and release of a drug. Proportion and number of charged sites in the 
drugs and ion-exchange groups change with pH. Hydrocarbon based backbone of the 
resin/fiber is hydrophobic and, thus, binding between the drug and the resin increases 
with increasing drug lipophilicity. It could be assumed that hydrophilic drugs were 
incorporated better into the ion-exchangers with a hydrophilic backbone (e.g., viscose). 
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However, Hänninen et al. (2001) found no difference in the incorporation of ten salicylic 
acid derivatives (log Poct varied from 1.5 to 3.0) into the ion-exchange fibers with 
hydrophilic (viscose) or hydrophobic (polyethylene) backbone. The increasing drug 
concentration in the resin/fiber increases also the amount of released drug. The fraction 
(percentage) of the drug release is the same by the same resin and drug (Conaghey et al., 
1998b). However, the rate to reach this level was different depending on the drug 
concentration in question. The ion-exchange groups of the resin or fiber can be either 
strong or weak exchangers or a mixture of them both. A strong exchanger binds a drug 
strongly and it is released slowly. In contrast, a weak exchanger binds a drug weakly and, 
therefore, the drug is released quickly. The degree of grafting may obviously affect the 
drug release depending on the physico-chemical properties of the drug.  
 
The binding strength of drugs into the ion-exchange systems is due to both the 
electrostatic and hydrophobic interactions (see section 2.3.3). Ion-exchange resins, which 
have a small particle size, bind and release significantly more drug (adsorption and 
release rates are also faster) than the resins with larger sized particles (Burge et al., 1986; 
Irwin et al., 1987; 1990; Conaghey et al., 1998b; Sriwongjanya and Dodmeier, 1998). 
The release of a drug could be increased or decreased by adjusting the degree of cross-
linking of a resin. Both the small particle size and increase in the cross-linking in the 
resin leads to a large surface area to unit volume ratio, which causes higher adsorption 
with weak hydrophobic interactions. On the other hand, the increased cross-linking may 
hinder the movement of a drug through the resin and, thus, decrease the drug release. In 
general, increase in the ionic strength causes increase in the drug release (Irwin et al., 
1987; Sawaya et al., 1988; Jenquin et al., 1990; Conaghey et al., 1998a). Increase in the 
electrolyte concentration decreases the Donnan potential and, hence, the electrostatic 
affinity between the drug and the ion-exchanger, thus tending to increase drug release 
(Åkerman et al., 1998). The ionic strength of the loading solution influences the drug 
binding and release from the ion-exchanger. If the drugs are loaded in pure water (as 
compared to a buffer medium), weaker interactions with the ion-exchange materials are 
observed and the drug release takes place more easily. Thus, the adsorption of the drug 
into the ion-exchanger is decreased with the increasing ionic strength of the buffer 
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medium (Jenquin et al., 1990; Conaghey et al., 1998b, Åkerman et al., 1999).  This 
decrease in drug adsorption into the ion-exchanger may be due to the inhibition of 
electrostatic binding of the drug by the presence of other ions. 
  
Due to the different affinity of molecules to the ion-exchanger, the molecules in the 
external solution also affect the drug release. For example, calcium ions are known to 
adsorb more strongly than sodium ions, especially to carboxylic groups (Sawaya et al., 
1988; Charman et al., 1991; Sørensen and Rivera, 1999). Generally, increasing the charge 
of the salt increases the binding affinity into the ion-exchange groups, which obviously 
increases the drug release (Helfferich, 1995). However, increase in the charge density of 
ion-exchange material may crosslink the hydrocarbon network of the resin and, thereby, 
hinder drug release (Kriwet and Kissel, 1996). If one considers transdermal drug 
delivery, several salt molecules may cause skin irritation and, therefore, one may use only 
few additive salts on the skin. Optimization of the external coion concentrations so that 
all the coions bind into the ion-exchanger will, however, prevent the irritation effect of 
the salt.  
 
In ion-exchange fibers, the rate of ion-exchange has been found to rise with the increase 
of temperature (Chen et al., 1996). Other researches have observed the same with resins 
(Irwin et al., 1990; Jenquin et al., 1990). The observation can be explained as the 
increased molecular movement caused by the increased temperature. Although the 
changes in temperature may affect the drug release, the temperature of a transdermal drug 
delivery device may not differ considerably from a physiological temperature on the skin. 
The temperature has also an effect on the incorporation of a drug into the resin. Drug 
loading at a higher temperature provides a lower release rate despite the greater drug 
content in the resin (Irwin et al., 1990). Drug ions penetrate probably into deeper 
exchange centers in the resin due to the heat. The ion-exchange rate increases also with 
the increase of stirring speed (Irwin et al., 1990; Chen et al., 1996). When the stirring 
speed increases, the thickness of the adherent film decreases, and this in turn leads to the 
increase in the ion-exchange rate. 
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2.3.5 Ion-exchange fiber vs. resin 
  
Ion-exchange material may consist of, e.g., ion-exchange resin, gel or fiber (Jones et al., 
1989; Irwin et al., 1990; Jenquin et al., 1990; Chen et al., 1996; Lin and Hsieh, 1996; 
Conaghey et al., 1998a; 1998b). Ion-exchange resins and gels have crosslinked grafted 
side chains, which the fibers do not have (Fig. 2) (Ekman, 1994; Helfferich, 1995). Drug 
release kinetics from the previous ion-exchangers differ from each other (Chen et al., 
1996). Drugs were released significantly faster and to a larger extent from the ion-
exchange fibers than from the gel or resin. The most ion-exchange processes in resin and 
gel are controlled by particle diffusion (Lin and Hsieh, 1996). This is also the case for the 
fiber. Chen et al. (1996) assumed that the enhanced rate of ion-exchange in the fiber is 
due to the smaller shell thickness of the fiber as compared to the shell thickness of a 
resins. Small shell thickness of the fiber allows the ions a rapid access to the ion-
exchange groups. Also, ion-exchange fiber (especially the staple fiber) is suggested to 
have a larger surface area to unit volume ratio, which leads to a higher adsorption rate 
and adsorption capacity (and, presumably, also to a higher release rate as compared to the 
resin or gel). Furthermore, one could easily presume, that molecules with high molecular 
weight could be incorporated more easily into the ion-exchange fiber than into the resins 
or gels that include cross-linked grafted side chains. Thus, cross-linking could hinder the 
incorporation (and release) of biomolecules into (from) the resin.  
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3 AIMS OF THE STUDY 
 
The main purpose of this study was to investigate the properties of the cation- and anion-
exchange fibers to store drugs and to deliver drugs transdermally. The specific aims can 
be summarized as follows: 
 
1) To understand drug adsorption phenomena into the ion-exchange fibers. 
 
2) To determine the kinetics of drug release from the fibers, especially to study the 
influence of external conditions, drug properties, and fiber quality on the drug release 
from the ion-exchange fibers. 
 
3) To study the effect of ion-exchange fiber on drug stability. 
 
4) To determine in vitro the flux of drugs through the human stratum corneum, with and 
without iontophoretic current, and the effect of ion-exchange fibers on that flux. 
 
5) To determine, whether clinically relevant plasma concentrations of tacrine in human 
volunteers could be achieved using short-term iontophoretic transdermal drug 
delivery utilizing ion-exchange fiber approach. 
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4 EXPERIMENTAL 
 
4.1 Materials (I-IV) 
 
Tacrine(-HCl) (I-III), propranolol(-HCl) (I, II), nadolol (I, II), metaraminol (bitartrate 
salt) (IV), and zwitterionic levodopa (IV) were obtained from Sigma (St. Louis, MO, 
USA). Salicylic acid (sodium salt) (I) was from Aldrich-Chemie (Steinheim, Germany). 
Chemical structures and physico-chemical properties of the model drugs are presented in 
Table 3. N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid (HEPES for the buffer) (I, 
IV) and ethylenediaminetetraacetic acid (EDTA, chelating agent) (IV) were from Sigma 
(St. Louis, MO, USA). D(+)-mannitol, was obtained from Merck (Darmstadt, Germany) 
(IV) and the radiolabeled D-(1-14C)-mannitol (54,50 mCi/mmol, purity > 97 %) (IV) was 
from Dupont NEN Products (Boston, USA). Deionized water (resistivity ≥ 18 MΩcm-1) 
was used to prepare all the solutions. All the other chemicals were analytical grade and 
were used without further purification.  
 
Cation-exchange fibers Smopex-101 [-SO3H ion-exchange groups, poly(ethylene-g-
styrene sulphonic acid) fiber] (II, IV), Smopex-102 [-COOH ion-exchange groups, 
poly(ethylene-g-acrylic acid) fiber] (I-IV) and Smopex-107 [1:1 -COOH and -SO3H 
ion-exchange groups, poly(ethylene-g-acrylic acid-co-vinyl sulphonic acid) fiber] (II) 
and anion-exchange fibers Smopex-103 [trimethylammonium ion-exchange groups, 
poly(ethylene-g-vinylbenzyltrimethylammoniumchloride) fiber] (IV), Smopex-105 
[pyridine ion-exchange groups, poly(ethylene-g-vinylpyridine) fiber] (IV) and Smopex-
108 [-NH2 ion-exchange groups, amidoxime functional fiber] (I) were obtained from 
Smoptech Ltd. (Turku, Finland). Maximal ion-exchange capacity of the 101-fiber was 3.2 
(II) and 4.0  (IV) mmol/g, 102-fiber 8.0 (I, II) and 12 (IV) mmol/g, 107-fiber 8.0 mmol/g 
(II), 103-fiber 3.5 mmol/g (IV), 105-fiber 6.0 mmol/g (IV) and 108-fiber 3.4 mmol/g (I). 
Ion-selective Nafion membrane, used in the in vivo permeation experiments (III), was 
purchased from ElectroCell AB (Täby, Sweden), and Durapore porous membrane from 
Millipore (Ireland) (III). 
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Table 3. Physico-chemical properties of the drugs studied (Drayton, 1990): 
MW = molecular weight, Ka = dissociation constant, and Poct = octanol/water 
partition coefficient. ^our determination 
 
Drug MW (g/mol) pKa log Poct molecule structure 
Tacrine 198.0 9.8±0.2^ 3.3 
 
 
Propranolol 259.1 9.23 3.2 
 
 
Nadolol 309.4 9.39 0.9 
 
 
Metaraminol 167.2 8.6 -0.27 
 
Levodopa 197.2 
2.3; 8.7;     
9.7; 13.4 
-2.9 
 
 
Sodium salicylate 
 
160.1 
 
3.0 
 
1.5 
 
 
 
 
4.2 Subjects (III) 
 
Ten healthy adult volunteers (5 males and 5 females) were included in the experiments 
(III). The age of the study subjects ranged from 19 to 52 years, and the body weight of 
the subjects was 50 - 86 kg. All the study subjects signed an informed consent, and they 
were given information about tacrine and the protocol of the experiments. The studies 
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were approved by the ethical committee of the Helsinki University Hospital and Finland′s 
National Agency for Medicines. A physician supervised the experiments and followed 
the well-being of the volunteers. The blood samples were taken by a registered nurse. 
 
4.3 Methods (I-IV) 
 
4.3.1 Preparation of the drug containing ion-exchange fiber discs/bundles (I-IV) 
 
To study drug binding capacity and drug release, circular discs (diameter 15 mm) were 
cut from the cation- and anion-exchange fibers (I, II). The weight of the discs was 40-
100 mg depending on the fiber. Thickness of the Smopex-107 fiber was about 3 mm, 
Smopex-102 fiber about 6 mm, and Smopex-101 fiber was like a cotton clothing (II, 
III). In the study with levodopa and metaraminol (IV), the Smopex-101, -102, -103 and 
-105 were used as staple fibers. Polyethylene backbone of the fiber was grafted by 
radiation with polyacrylic acid (Smopex-102), polysulphonic acid (Smopex-101) or 
both the polyacrylic acid and polysulphonic acid (Smopex-107), trimethylamine 
(Smopex-103), pyridine (Smopex-105) or by polyamine (Smopex-108). Thus, the 
cation-exchange groups were carboxylic or sulphonic acids and the anion exchange took 
place by tertiary amines, pyridine and primary amines, respectively. To increase ion-
exchange capacity (I), the cation-exchange fiber discs were treated with 1 M nitric acid 
solution until all the sodium was exchanged (3 h). Thereafter, to remove the acid, the 
fiber discs were washed with purified water until the pH was about 4.5. The ion-exchange 
discs were immersed overnight in 5 % (m/V = 50 mg/ml) tacrine(-HCl) (5.3 mmol), 
propranolol(-HCl) (4.2 mmol) or nadolol (4.1 mmol) solution (25 ml). Anion-exchange 
fiber (Smopex-108) was treated with 1 M NaOH solution and washed with purified 
water until the pH was 8.5. To load the drug to the discs, 5 % (m/V) sodium salicylate 
(7.8 mmol) solution was used (25 ml). To remove the unattached drug, the squeezed discs 
were then washed repeatedly with a total of 150 ml of purified water and dried at room 
temperature (I).  
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In the drug release studies (II, IV) the cation-exchange fiber discs/bundles were treated 
with 0.1 M NaCl solution or 0.1 M NaCl/0.1 M NaOH (1:1) solution and the anion-
exchange fiber bundles with 0.1 M HCl solution for about half an hour. Thereafter, the 
fiber discs were washed with purified water. The fiber discs/bundles were immersed in 1 
% (m/V) tacrine(-HCl), propranolol(-HCl), nadolol (II) and in 0.5 % 
metaraminol(bitartrate) or 0.1 % levodopa (IV) solutions (100 ml) three times 
consecutively. At the first and second times the discs were kept in the solution for three 
hours and for the third time overnight (about 12 h). After each immersion, the discs were 
washed with purified water. The fiber bundles were immersed in a 0.1 % levodopa 
solution at pH 2.0, 7.4 or 10.0 or in a 0.5 % metaraminol(bitartrate) solution at pH 2.0 or 
7.4, depending on the experiment (IV). The amount of adsorbed drug in the fiber discs 
was determined by HPLC from the combined washing solutions (I-IV). 
 
4.3.2 Drug release studies (I, II, IV) 
 
In the preliminary studies (I), drug release from the cation-exchange fiber discs was 
tested in Franz diffusion cells (Crown Glass Co., Somerville, NJ) at 25°C. The fiber discs 
were placed in the diffusion cells so that one side of the ion-exchange fiber was exposed 
to the dissolution medium (3.0 ml of HEPES-buffered saline, pH 7.4). The surface area of 
the fiber discs exposed to the buffer was 0.64 cm2. Samples were collected at fixed 
intervals for 24 h (1, 5, 10, 15, 20, 25, 30 and 45 min, 1, 2, 4, 6, 8, 12 and 24 h) and drug 
concentrations in the samples were determined by HPLC. 
 
In the more thorough experiments (II, IV), drug release from the cation-exchange fibers 
Smopex-101 and -102 (II, IV) and anion-exchange fibers Smopex-103 and -105 (IV) 
were tested in vitro in glass dish (with bottle top) at a temperature of 25°C. Drug 
containing fiber discs were separately placed in NaCl solutions (0.0015 M, 0.015 M, 0.15 
M and 1.5 M). Each NaCl solution contained an equimolar concentration of the salt as the 
concentration of the drug was in the fiber. To measure drug release from the fiber, the 
NaCl solutions were changed five times during a week (24, 48, 72, 96 and 168 h) (II) or 
two days (1, 2, 4, 6, 10, 24, 48 h) (IV). Effects of pH and ion-exchange groups on the 
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drug release were studied with a zwitterionic, easily oxidized levodopa, and with a 
cationic (presumably more stable) metaraminol (IV). In the studies with levodopa and 
metaraminol, the volume of the NaCl solution was 10 ml, regardless of the concentration 
of drug in the fiber (IV). The fiber discs were washed with mQ-water (10 ml) and 
squeezed, the washing solutions were collected, and the released drug concentrations in 
these solutions were determined by HPLC. In addition to drug release tests in NaCl 
solutions, tacrine release from the Smopex-101, -102 and –107 fibers was tested in the 
presence of 10%/90%, 50%/50% and 90%/10% CaCl2/NaCl solutions (II). The total 
NaCl+CaCl2 concentration was 0.015 M in each case. The release of levodopa from the 
Smopex-102 fiber was also tested in a 100 % CaCl2 solution (0.15 M) at pH-values 2.0 
and 7.4 (IV). In these experiments, the fibers were activated with 0.1 M NaCl/0.1 M 
NaOH solution.  
 
Drug release with iontophoretic current from the cation-exchange fiber discs was tested 
in vitro in Side-by-side-diffusion cells (Crown Glass Co. Inc., Somerville, NJ) (I). In 
these experiments the samples (50 µl) were collected also from the donor compartment at 
1, 2, 4, 6, 8, 12 (current off), and 24 h during the permeation experiments in vitro. 
 
4.3.3 Source and preparation of skin (I, IV) 
 
The membrane tissue was human cadaver skin from Kuopio University Hospital (I) and 
Helsinki University Hospital (IV). Each skin sample was heated two minutes in 60°C 
water (Gummer, 1988), and the epidermis was separated using surgeon′s knife. The 
samples were dried at room temperature and cut into 3 cm x 3 cm pieces, which were 
kept in a freezer until used. 
 
4.3.4 Transdermal permeation experiments in vitro (I, III, IV) 
 
Side-by-side-diffusion cells (I, IV): In vitro permeation studies were performed in 
Side-by-side-diffusion cells (Crown Glass Co. Inc., Somerville, NJ (I), Laborexin, 
Helsinki, Finland (IV)) at a room temperature. Permeation studies were performed with 
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tacrine, propranolol, nadolol, sodium salicylate (I), levodopa and metaraminol (IV). The 
human stratum corneum was clamped between the two identical halves of the diffusion 
cell. The area of exposed skin was 0.64 cm2 (I) or 0.785 cm2 (IV). HEPES-buffered, 
physiological NaCl (pH 7.4 (I, IV) and 4.0 (IV)) was placed in the receiver 
compartments of the diffusion cells. Drug containing ion-exchange fibers or the drug 
solution (tacrine, propranolol, nadolol or sodium salicylate 150 mg/3 ml (I); metaraminol 
8.0 mg/3 ml or levodopa 5.0 mg/3 ml (IV)) were placed in the donor compartment in the 
same buffer. Positively charged drugs were iontophoresed from the anodic compartment; 
the negatively charged drug was delivered from the cathode. Samples (250 µl) were 
collected from the receiver compartment and replaced by fresh buffer at 1, 2, 4, 6, 8, 12 
(current off), and 24 h (I) and at 0.5, 1, 2, 3, 4, 5 and 6 h (IV). 
 
Franz-type diffusion cells (III): Permeation studies of the tacrine formulations were 
performed across the excised human epidermis (Helsinki University Hospital) in vitro in 
Franz-type diffusion cells (Laborexin Oy, Helsinki, Finland) at a room temperature. The 
area of the exposed skin was 2.41 cm2. The test formulations were placed in the donor 
compartment, and HEPES-buffered physiological NaCl was placed in the receiver 
compartment. Samples (200 µl) were collected from the receiver compartment and 
replaced by fresh buffer at 30, 60, 90, 120, 150, 180 (current off), and 240 min. The 
current source used was Phoresor II Auto (Iomed Inc., Salt Lake City, USA), the same 
as was used in the in vivo experiments (see section 4.3.5). 
 
Iontophoretic apparatus (I, IV): Silver-silver chloride electrodes were used in all the 
iontophoretic experiments (Green et al., 1991). Ag/AgCl-electrodes were preferred to 
platinum electrodes because of avoiding changes in pH due to electrolysis of water. 
During the experiments the electrodes were separated from the donor and receptor 
chambers by salt bridges, which consisted of 1 M NaCl gelled with 3 % agarose inside 
plastic tubing (diameter 4 mm, length ca. 15 cm). Salt bridges prevented direct contact 
and possible reactions of the drugs with the Ag/AgCl-electrodes. The electrolyte that 
surrounded the electrodes was HEPES (25 mM) buffered saline (0.15 M) at pH 7.4. A 
constant current (6181C DC Current Source, Hewlett Packard, USA (I), Ministat current 
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source, Sycopel Scientific Ltd., Boldon, England (IV)) of 0.1 mA/cm2 (I), 0.25 mA/cm2 
(I), and 0.5 mA/cm2 (I, IV) was applied for 6 h (IV) or 12 h (I), and for the next 12 h the 
passive flux was monitored (I). The current/voltage was monitored throughout each 
experiment (F2378A multimeter, Hewlett Packard, USA). 
 
Data analysis (I, III, IV): The amount of drug that had permeated through the human 
stratum corneum during a given time interval was calculated from the concentrations 
measured in the receptor compartment, which were corrected for sampling dilution and 
volume. Steady-state fluxes, Jss (µg/h per cm2 or nmol/h per cm2), were calculated by 
linear regression of the linear portion of permeation curves. All the experiments were 
performed at least three times. 
 
To determine whether a clinically relevant steady-state concentration of a drug in the 
plasma (Css, ng/ml) during transdermal drug delivery could be achieved, Css was 
calculated using the equation  
 
Css = A J/ CL    (Equation 4),  
 
where A is the surface area for drug absorption, J is the steady-state flux (µg/h per cm2), 
and CL (l/h) is the pharmacokinetic clearance of the drug from the body (Notari, 1987). 
 
4.3.5 Transdermal permeation experiments in vivo (III) 
 
Tacrine permeation (III): The in vivo experiments were performed using a battery 
operated (9 V) constant current source Phoresor II Auto (Iomed Inc., Salt Lake City, 
USA). In the first experiment (Test I) the electrodes were commercial Iogel-electrodes 
(Salt Lake City, USA). The system was the same as used by Ashburn et al. (1995) to 
deliver fentanyl citrate across the skin. The structure of a custom-built transdermal device 
used in the second test (Test II), is shown in Fig. 4. Silver-silver chloride electrodes were 
used for current delivery. Next to the anode and cathode electrodes was 1.5 M NaCl 
solution to maintain proper current delivery. Ion-selective Nafion-membrane prevents 
 the drug molecules from getting into the opposite direction. The heart of this device was 
ion-exchange fiber (Smopex-102), wherein the model drug, tacrine, was attached. 
Physiologic NaCl solution in the fiber compartment ensured a predetermined drug release 
for tacrine permeation. Positively charged drug is released by the Na+-ions. The area of 
these devices on the skin was 10 cm2. The total amount of free tacrine in each experiment 
was adjusted to 64 mg. The porous membrane was against the skin. A constant current of 
0.4 mA/cm2 was applied for 3 h on the ventral forearm of the volunteers. For the next 1 h 
passive tacrine flux was measured. The current/voltage was monitored throughout the 
experiments by a voltage/current meter (RTO3800G multimeter). To prevent painful 
sensations on the skin, the current was gradually increased from 0.1 to 0.4 mA/cm2 
during the first five minutes of the Tests I and II. The position of the electrodes was 
changed three times during the 3-hour experiment. 
 
Anode  +     Cathode - 
            
 
 
 
 
Figure 4. The structu
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sensations/symptoms during the tests and up to one week after the tests were finished. 
Also, a physician supervised the experiments and followed the well-being of the 
volunteers. In addition to Tests I and II, the possibly irritating effect of tacrine (no 
current) and iontophoresis (0.1 – 0.4 mA/cm2; no tacrine), on the skin of the volunteers 
was measured. 
 
4.3.6 Analysis of the drugs (I-IV) 
 
HPLC assays (I-IV): Drug concentrations in all the experiments were analyzed by high 
performance liquid chromatography (HPLC) (Beckman Instruments Inc., San Ramon, 
CA, USA (I-III), Thermo Separation Products Inc., San Jose, CA, USA (IV)). HPLC-
methods for the model drugs are shown in Table 4. 
 
Assay of serum tacrine concentrations (III): Venous blood samples of 10 ml were 
withdrawn from the volunteers at 30, 60, 90, 120, 150, 180 and 240 min. The withdrawn 
blood samples were centrifugated 30 min after the sampling, and plasma was separated. 
The plasma samples were kept in a freezer until analysis. Tacrine was extracted from the 
plasma in an extracting tube Chrompack Varian (Bond Elut-C18, Varian Inc., Harbor 
City, CA, USA), (McDowall, 1989). The extracting tube was regenerated by 1 ml of 
MeOH and 1 ml of purified water. One ml of the plasma sample was placed in the tube, 
whereafter the tube was washed with 1.5 ml of purified water. Tacrine was eluted using a 
6 ml solution of 22 % acetonitrile, 1 % triethylamine, and 77 % deionized water at pH 
6.5. The extracted tacrine solution was evaporated with air and dissolved in 200 µl of 
HEPES-buffered saline at pH 7.4. The linear concentration range for tacrine extraction 
was 5 - 250 ng/ml with a precision of ± 4.2 % (SD). 
  
Liquid Scintillation Counting (LSC) (IV): For the analysis of 14C-mannitol, 50 µl of 
the sample was mixed with 150 µl of deionized water and 4.5 ml of scintillation liquid 
(OptiPhase “HiSafe” 2, Wallac, Fisher Chemicals, Loughborough Leics, England). The 
14C-activities were measured by liquid scintillation counting using WinSpectral 1414 
Liquid Scintillation Counter (LSC) (Wallac, Turku, Finland). 
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Table 4. HPLC methods for the drugs used (I-IV). In each case the flow rate 
was 1.0 ml/min. The column was Supelcosil LC-18-DB (150 mm x 4.6 mm; 5 
µm; Supelco Inc., PA, USA) in the cases of tacrine, propranolol, nadolol, and 
sodium salicylate (I, II, III) and Luna C18 (150 x 4.6 mm; 5 µm; Phenomex, 
CA, USA) with levodopa and metaraminol (IV). 
 
drug 
Buffer 
(fraction) 
pH 
organic phase 
(fraction) 
wavelenght 
(λ) 
modified from 
reference 
tacrine 1 % TEA in mQ-water 
(0.78) 
6.5 ACN (0.22) 240 Forsyth et al., 1988 
propranolol 2 % TEA in acetate buffer 
(0.65) 
4.0 ACN (0.35) 289 Sutinen et al., 1990 
nadolol 1 % HSA in acetate buffer 
(0.75) 
4.0 ACN (0.25) 223 A new method 
sodium salicylate 50 mM potassium 
phosphate buffer (0.60) 
7.0 MeOH (0.40) 298 Hirvonen et al., 
1993 
levodopa 25 mM ammonium acetate 
in mq-water (0.99)  
4.1 MeOH (0.01) 282 Kafil and Dhingra, 
1994 
metaraminol 25 mM ammonium acetate 
in mq-water (0.95)  
4.1 MeOH (0.05) 272 Kafil and Dhingra, 
1994 
 
 
 
 
4.3.7 Statistical analyses (III) 
 
Possible statistical differences between the tacrine plasma levels in the in vivo studies 
(Tests I and II) were determined using a paired t-test. The standard deviations (a measure 
of biological variation) were proportioned to the average values, and tested for a possible 
difference by the paired t-test as well. Statistically significant level was set as p < 0.05.  
 
 29 
5 RESULTS AND DISCUSSION 
 
5.1 Drug binding/adsorption into the ion-exchange fibers (I, II, IV) 
 
Properties of the ion-exchange fiber and drug (II): Both strong (-SO3H) and weak (-
COOH) ion-exchange groups were studied. Table 5 shows the drug content of ion-
exchange fibers containing sulphonic groups (Smopex®-101 and –101*), carboxylic 
groups (Smopex®-102 and –102*) and their combination (Smopex®-107). From the 
columns corresponding to Smopex®-101, -101* and -102*, it can be observed that the 
drug content in the fiber increases with the increasing drug lipophilicity, but the results of 
–102 and –107 fibers are not unambiguous.  
 
Table 5. Drug content (mmol/g) in the Smopex -101, -102 and -107 ion-
exchange fiber discs. Fibers were activated with 0.1 M NaCl solution (101, 
102, 107) or 0.1 M/0.1 M NaCl/NaOH solution (101*, 102*). 
  
     Drug content (mmol/g) 
 Drug  Log Poct1 101       101* 102  102*         107 
 
 Tacrine 3.3  4.43   1.43  8.30        0.98 
 Propranolol 3.2  3.09   2.94  8.33        2.69 
 Nadolol 0.9  1.88   2.28  4.54        0.98 
 Metaraminol -0.27         0.83   0.76 
 Levodopa -2.9         0.10   0.50 
 
1Drayton, 1990 
 
The differences shown in Table 5 for a given drug in different fibers is a clear 
manifestation of the fact that the distribution equilibrium of the drug is affected by drug-
fiber interactions, which are specific to the ion-exchange group and the fiber nature. The 
strength of these interactions is quantified by the chemical partition coefficient (II). 
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Strong electrostatic bonds have a chemical nature and only ionized molecules are capable 
to be bound into this layer, where the concentration of binding molecules is usually very 
high (Conaghey et al., 1998b; Marchal-Heussler et al., 2000). Levodopa was shown to be 
bound into the ion-exchangers, although both the drug and fiber were partially charged by 
the same sign (IV, Table 3). Both the ionized and non-ionized drug molecules may also 
bind via loose hydrophobic interactions. These mechanisms could explain the 
incorporation of drugs into the ion-exchange fibers of similar charge. 
 
Activation of the ion-exchange fiber (II, IV): The effect of activation on the drug 
binding capacity of the ion-exchange fibers is clearly shown in Table 5. The binding 
capacity of the –102 fiber that was activated only with 0.1 M NaCl solution was clearly 
lower than the capacity of the fiber –102* that was activated also with NaOH. In the 
basic solution of NaOH, hydrogen ions are exchanged with sodium ions more easily than 
in the NaCl solution alone. The better adsorption was more obvious with the more 
lipophilic drugs. Tacrine (the most lipophilic drug) was bound into the –COOH groups of 
the ion-exchange fiber ca. six times better when the fiber was activated with NaOH. The 
maximal binding capacity of this Smopex-102 ion-exchange fiber is ca. 8.0 mmol/g (all 
the grafted ion-exchange groups occupied). Thus, when the fibers were activated with 
NaOH, all the binding places were filled with drug in the case of the more lipophilic 
drugs. In the case of the more hydrophilic nadolol, half of the binding groups were 
occupied, and with the very hydrophilic metaraminol and levodopa (log Poct are –0.27 and 
–2.9, respectively), the drug content was less than 1 mmol/g. There were also smaller 
amount of levodopa and metaraminol than other drugs in the adsorption medium. Due to 
the low solubility of levodopa and metaraminol, more concentrated drug solution could 
not been used.  
 
Drug concentration in the external solution (I, II, IV): Drug incorporation into the 
fiber was accomplished in three steps. At the first two times the drug incorporation was 
significantly greater than at the third time. At the beginning, the concentration difference 
between the drug in the solution and in the fiber was larger than during the last 
immersion, which probably explains the results observed. Thus, at the first step all the 
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binding places (ion-exchange groups) are free. Lin and Hsieh (1996) have observed the 
same. When the total number of drug ions in the solution, amount of fiber, temperature, 
and total absorption time were kept the same, higher drug adsorption was observed in the 
case of the greater concentration gradient of the drug. 
  
pH of the external solution (IV): According to Henderson-Hasselbalch equation 
(Martin, 1993), one may calculate the ionized % of the ion-exchange groups of the 
fiber(s) and of the drug at the pH-values studied. In Smopex-105 the ionizable group is 
pyridine, a weak base (pKa ≈ 5), which is ionized mainly at acidic pH-values (IV: Table 
1). The trimethylammonium group in the Smopex-103 is a strong base (pKa > 13), 
which is ionized at all the pH-values studied. Only a small fraction of the weakly acidic –
COOH –groups (pKa ≈ 4) of Smopex-102 are ionized at pH 2.0. In contrast, the strong 
ion-exchanger Smopex-101 (-SO3H –groups, pKa < 1) was totally in an ionized state at 
all the pH-values studied. The amount of levodopa adsorption into all the ion-exchange 
fibers was clearly reduced at pH 7.4 (as compared to pH 2.0 and 10.0), (IV: Table 2). 
Theoretically, levodopa possesses both a positive and a negative charge at pH 3-9 (Merck 
Index, 1996). When levodopa was changed into its HCl-salt (by dissolving it into a 0.1 M 
HCl-solution, IV: Fig. 3), the adsorption of levodopa into the Smopex-101 fiber was 
increased four-fold. Thus, although levodopa exists as a zwitterion at pH 7.4, it forms an 
intrinsic molecular salt with a net charge of zero. 
  
Summary of the properties of drug, ion-exchange fiber and external solution, which affect 
the binding of drugs into the ion-exchange fibers, is presented in Table 6.  
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Table 6. The properties of drug, ion-exchange fiber and external solutions, 
which affect the binding of a drug into the ion-exchange fibers. 
 
Property      Effect 
 
 
drug lipophilicity ↑ => drug content ↑  
(or no clear effect)  
 
ion-exchange groups   => specific interactions 
=> drug content ↑ or ↓ 
 
activation of fiber   => drug binding capacity ↑ 
      => drug content ↑  
drug concentration in the    
external solution ↑   => concentration gradient ↑  
    => drug content ↑ 
 
pH of external solution   => dependent on the pKa of drug    
      => drug content ↑ or ↓ 
 
 
5.2 Control of drug release from the ion-exchange fibers (I, II, IV) 
 
During their preparation, the cation-exchange fiber discs with the ion-exchange groups in 
hydrogen form were immersed in a solution of the cationic drug and chloride ions. The 
fiber tends to equilibrate with this bathing solution and exchange the hydrogen ions with 
the cationic drug, that compensate the negative fixed charge groups within the fiber. If 
the concentration of the cationic drug in the solution is sufficient and if enough time is 
allowed for this ion-exchange process, the fiber turns completely into drug form. If not, 
which is usually the case, the fiber contains both the cationic drug and hydrogen ions. 
Moreover, chloride ions are always present in the fiber phase in a concentration such that 
the local electroneutrality condition is satisfied (Donnan exclusion) (Helfferich, 1995). 
 
Properties of the drug (I, II): The fiber discs containing cationic drugs were placed in 
the Franz cell and the passive drug release into HEPES-buffered physiological saline was 
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followed (I). The release rate observed was larger for nadolol (hydrophilic) than for 
tacrine and propranolol (both lipophilic), which shows the dependence of the release rate 
on the lipophilicity of the drug (I: Fig. 1).  
 
In publication II the drug release kinetics were studied in a more detailed way. The more 
lipophilic drugs tacrine and propranolol were attached more strongly to the strong ion-
exchange groups (Smopex-101, -SO3H groups), and were released more easily from the 
fibers containing weak ion-exchange groups (-COOH) (II, Fig. 1). Hydrophilic nadolol 
was released most rapidly from the Smopex-101 fiber. The release of nadolol from 
Smopex-101 was over ten times higher than that of tacrine from this fiber, while it was 
only about two times higher in the case of Smopex-102 fiber. This indicates that the 
specific interactions of the lipophilic drugs with the sulphonic acid fiber are stronger than 
with the carboxylic acid fiber, while the opposite is true for the interaction of nadolol 
with these fibers (II). Other researchers have found the same effect, e.g., Sprockel and 
Price (1989) observed that chlorpheniramine (log Poct 3.39 (Drayton, 1990)) was released 
more quickly from a carboxylic acid resin than from a sulphonic acid resin. 
 
Of course, the ion-exchange fiber and the drug in question have to be suitable to each 
others. E.g., strong ion-exchangers could cause hydrolysis of labile drugs, because they 
are effective acid-base catalysts (Anand et al., 2001).  
 
Drug content in the fiber (II): Activation of fibers with NaOH increased drug binding 
into the ion-exchange groups, but the fraction of the drug content that was released in 
every case remained about same (II). Tacrine release from the Smopex-102 fiber in the 
0.015 M NaCl solution in one week was 9.4 ± 2.1 % when the tacrine content in the fiber 
was 1.43 mmol/g, and 8.7 ± 0.85 % with the tacrine content of 8.30 mmol/g. 
Correspondingly, with propranolol the release was 10.6 ± 0.29 % at 2.94 mmol/g drug 
content and 12.8 ± 0.27 % when the drug content was 8.33 mmol/g. Thus, although the 
drug content in the fibers increased and the amount of drug release increased, the relative 
fraction (%) of the drug release was constant. Conaghey et al. (1998b) have observed the 
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same influence with ion-exchange resins, a constant fraction of drug was released from 
the resin although the total drug content in the resin was increased. 
 
Salt concentration (II, IV): The drug can not be released from the ion-exchanger in 
water, since there are no counter ions in the medium to replace drug ions from the ion-
exchanger. Therefore, counter ions are always needed in the dissolution medium 
(Sriwongjanya and Bodmeier, 1998). The effect of the extracting salt concentration was 
similar for all the drugs. In general, drug release from the ion-exchange fibers was faster 
at lower concentrations of NaCl (II: Fig. 1). The volume of the extracting salt solution in 
these drug release experiments with 1.5 mM NaCl was 1000 times larger than in the 
experiments with 1.5 M NaCl, and this volume difference had a clear effect on the drug 
release. The change in electrolyte concentration has two competing effects on the drug 
release. Firstly, increasing electrolyte concentration decreases the Donnan potential and, 
hence, the electrostatic affinity between the drug and the fiber, thus tending to increase 
drug release. Secondly, a large electrolyte concentration implies a small volume of the 
external solution and then a very small amount of drug release is needed to reach the 
equilibrium drug concentration in the external solution. This latter volume effect was 
obviously dominant in this study (II). 
 
The experimental setup of the study above was different from the most studies in the 
literature. Typically the same external solution volume has been used for the different 
electrolyte concentrations. With metaraminol tests, the volume of external solution was 
kept the same and the NaCl concentration was varied (IV). The higher the NaCl-
concentration, the higher the drug release was observed (IV: Fig. 4). The work of 
Conaghey et al. (1998a) showed that nicotine was released more slowly from ion-
exchange resin at lower ionic strengths of the release medium. The same effect has also 
been observed in other studies of ion-exchange resins (Irwin et al., 1987). Bodmeier et al. 
(1996) observed that the drug release rate from the resins initially increased with the 
increasing buffer strength and then decreased at even higher buffer strengths. The 
structure of ion-exchange fibers is arranged like a cloth (Fig. 2), whereas ion-exchange 
resins have a cross-linked hydrocarbon network with attached ionizable groups (Florence 
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and Attwood, 1998). Åkerman et al. (1999) have studied drug release from poly(acrylic 
acid) grafted poly(vinylidene fluoride) membranes at different ionic strengths. They 
observed that the release rate of propranolol decreased significantly with the increasing 
ionic strength of the dissolution medium, probably due to a cation-exchange process and 
swelling behaviour of grafted poly(acrylic acid) chains. A corresponding trend was also 
observed with other small molecules. Those results are similar to the present studies with 
the ion-exchange fibers (II). 
 
pH (IV): The pH of the external solution had a clear effect on the release rate of drugs 
depending on the pKa of drug and ion-exchange group of the fiber. When the ion-
exchange group and levodopa/metaraminol possessed the same charge, there were only 
loose hydrophobic interactions between the fiber and drug. From these loose interactions 
the drug release was clearly faster than from the ionic interactions. Practically all the drug 
was released at the initial stage (within 1 hour).   
 
Salt choice (II, IV): Since tacrine and levodopa were very strongly attached to the fibers, 
the release of tacrine and levodopa was studied with solutions containing also CaCl2 at a 
fixed total concentration (II, IV). Even 10 % of CaCl2 had a profounded effect on the 
drug release, virtually all tacrine was released in the third equilibrium stage (72 h) from 
Smopex-102 fiber and Smopex-107 fiber (II: Fig. 2). Thus, the release was increased 
ca. 3-4 times with CaCl2 as compared to NaCl-solution alone. The release of levodopa 
from the Smopex-102 ion-exchange fiber was very small (< 1 %) at pH 7.4 (NaCl 
solutions). In 0.15 M CaCl2-solution, 44 % of levodopa was released from the Smopex-
102 fiber. The interaction of calcium ions with the ion-exchange groups of the fiber was 
clearly stronger than the interaction of sodium ions. Calcium ions are known to bind 
strongly to carboxylic groups, but not that strongly to sulphonic groups (Charman et al., 
1991; Sørensen and Riviera, 1999). The reason for the improved binding affinity of 
calcium to ion-exchange groups over the sodium ions is caused by the +2 charge of 
calcium. Cation-exchange tends to have affinity in the decreasing order for calcium, 
potassium, sodium, ammonium and hydrogen ions (Florence and Attwood, 1998). Table 
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7 presents the summary of properties, which affect the drug release kinetics from the ion-
exchange fibers. 
 
Table 7. The properties of drug, ion-exchange fiber and external solution, 
which affect the release rate of a drug from the ion-exchange fibers. 
 
 
Property      Effect 
 
 
drug lipophilicity ↑   => release rate ↓ 
 
drug content in the fiber ↑ or ↓  => relative release rate (%) the same 
 
ionic strength ↑    => release rate ↑ 
 
ionic strength ↑ + volume ↓  => release rate ↓ 
 
volume of external solution ↑  => release rate ↑ 
 
pH ↑ or ↓     => release rate ↑ or ↓ 
 
salt choice => specific interactions => release rate ↑ or ↓ 
 
 
 
5.3 Drug stability (IV) 
 
The structure of levodopa is similar to a hydroquinone structure (double-OH-substituted 
aromatic ring) (IV: Fig. 1a). Hydroquinones can be oxidized to quinones, which involves 
a two-one electron transfer step (Hovorka and Schöneich, 2001). The oxidation process 
proceeds with very mild oxidizing agents, such as Ag+ or Fe3+ present, e.g., in moisture 
or water. The oxidation of levodopa can be observed also visually, because the 
hydroquinones are colourless and the quinones are coloured (Fessenden and Fessenden, 
1990). The oxidation of levodopa (in solution) was fast present especially in basic 
solutions (IV: Fig. 3). Already at one hour time-point, the initially clear 1.0 mg/ml 
solution of levodopa had turned into a dark colour, and significant part of levodopa was 
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oxidized at basic pH-values. When levodopa is oxidized, the hydrogen atoms come off 
and, therefore, in an acidic environment the oxidation of levodopa is hindered.  
 
In the adsorption, release and permeation studies with the ion-exchange fibers, the 
concentration of levodopa remained unchanged at least for 48 hours at pH-values of 2.0, 
4.0 and 7.4. Drug concentration was the original ± 5 % in all the cases. Permeation of 
levodopa from the ion-exchange fiber and solution formulation across the skin was 
studied at pH 7.4 (IV). Levodopa was oxidized significantly during the first 6-8 hours in 
the solution formulation, whereas in the ion-exchange fiber formulation levodopa was not 
oxidized during the 24-hour experiment. Thus, the ion-exchange fibers may provide a 
good choice in improving the stability of drugs during storage in water. The drug 
adsorbed into an ion-exchange material may be stored in wet/dry conditions, and the 
extracting salt may be introduced only immediately prior to the application of the 
medication into a patient. An additional advantage is the buffer-like behavior of the ion-
exchange material (Helfferich, 1995), that holds the pH of the release medium constant. 
 
5.4 Drug permeation studies in vitro (I, III, IV) 
 
5.4.1 Drug permeation from solution formulations (I, IV) 
 
Transdermal permeation of the model drugs across the human skin at pH 7.4 was studied  
both under passive and iontophoretic conditions (I = 0.5 mA/cm2). The lag-time for 
permeation was about 24 h in the case of passive flux and 0.5 h in the case of 
iontophoretic flux (I). Since all the drugs (Table 8) were delivered from a 5 % solution, 
the differences observed in the passive flux values were obviously related to the nature of 
the drug. The hydrophilic drug nadolol exhibited the lowest passive flux, thus showing 
that it hardly enters the skin. The lipophilic drugs (tacrine, propranolol and salicylate) 
permeated the skin at a much faster rate than nadolol, but the differences observed do not 
correlate well with their octanol/water partition coefficients (see Tables 3 and 8). 
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Table 8. Passive and iontophoretic fluxes (µg/h per cm2) across human skin in 
vitro from a 5 % (m/V) solution. Direct current iontophoresis (0.5 mA/cm2) 
was on for 12 h. Mean ± standard deviation, N = 4-7. 
 
Drug passive flux iontophoretic 
flux 
enhancement 
factor 
Tacrine 3.0 ± 0.7 220 ± 50 70 
Propranolol 0.26 ± 0.07 43 ± 7 170 
Nadolol 0.04 ± 0.05 49 ± 7 1200 
Sodium salicylate 0.34 ± 0.07 45 ± 6 130 
 
Clear increase of transdermal permeation during iontophoresis was observed for all the 
drugs (Table 8). The enhancement factor, E, [E = Jiontophoresis/Jpassive (Srinivasan and 
Higuchi, 1990, Kontturi and Murtomäki, 1996)] varied from 70 to 1200. The largest 
enhancement was found for the most hydrophilic drug, nadolol, which has been reported 
also earlier (Hirvonen and Guy, 1997). The lowest enhancement factor corresponded to 
tacrine, which exhibited the largest passive flux.  
 
Permeation of levodopa and metaraminol across the human skin was also studied in vitro 
(IV). A small increase in transdermal levodopa permeation by iontophoresis was 
observed (E = 3), although the net charge of levodopa was zero and the electroosmotic 
solvent flow was about zero at the pH 4.0 of the study. Iontophoresis, thus, increases the 
permeability of skin (Sims et al., 1991). Using iontophoresis, the positively charged 
metaraminol permeated across the skin significantly more than the zwitterionic levodopa 
(IV, Figs. 5a and 5b), largely, obviously, due to the electrorepulsion. Enhancement factor 
of metaraminol permeation from the solution was 932, close to the E-value of nadolol. 
 
The permeation rate of tacrine was studied as a function of the iontophoretic current 
density (I), from 0 (passive) to 0.5 mA/cm2, which is considered the upper limit for safe 
iontophoresis (Burnette, 1988). The iontophoretic permeation rate remained constant 
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until the current was switched off, and its value was directly related to the iontophoretic 
current density I (I: Fig. 3). This is in accordance with several literature reports (Behl et 
al., 1989; Srinivasan et al., 1989; Delgado-Charro et al., 1995; Conaghey et al., 1998b). 
After current termination the transdermal permeation rate of tacrine returned rapidly to 
the passive level, which indicates that iontophoretic flux enhancement does not lead to 
permanent changes in the skin permeability.  
 
5.4.2 Drug permeation from ion-exchange fibers (I, III, IV) 
 
Figure 5 presents a schematic model of transdermal drug delivery using iontophoresis and 
cation-exchange fiber.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. A schematic model of iontophoretic drug delivery by ion-
exchange fiber. 
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If one wants to achieve steady-state flux of drugs across the skin, concentrations of the 
drug and mobile ions in the bathing solution of the donor compartment need to be 
constant. Direct current iontophoresis is the way to achieve constant drug flux across the 
skin. The validity of this assumption was tested by taking samples in both the donor and 
receiver compartments of the diffusion cell (I). Tacrine concentration in the donor 
chamber and the flux across the skin during iontophoretic delivery increased for 3-4 
hours (Fig. 6). After that, tacrine concentration in the donor chamber and the flux of 
tacrine across the skin remained constant. This indicates that at steady-state the amount of 
tacrine released from the fiber equals the permeation of the drug across the skin as long 
as the current is turned on. 
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Figure 6. Amount of tacrine in the donor (ο) and the receiver (•) compartments 
during iontophoretic delivery across the human skin from Smopex-102 ion-
exchange fiber in vitro. Current density was 0.5 mA/cm2. The current was on 
for 12 h, whereafter passive drug permeation was followed up to 24 h. Mean ± 
SD, N = 6. 
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The comparison between the passive permeation rates of tacrine across the skin from the 
5 % solution and from the ion-exchange fiber is interesting. The passive permeation rate 
from the solution (drug content 150 mg) was 3.0 ± 0.7 µgh-1cm-2, while that from the ion-
exchange fiber (drug content 7.6 mg in fiber) was merely 0.003 µgh-1cm-2. The factor 
1000 between these two fluxes is explained by drug concentrations. While the 5 % 
solution contained 150 mg of tacrine, the amount of free tacrine released from the fiber 
was only about 2 %, which corresponds to 0.15 mg. Thus, the ion-exchange fiber seems 
to be an excellent drug reservoir that holds almost all the drug tightly in the ion-exchange 
groups (I). Similar behaviour as with tacrine was also observed with the other positively 
charged model drugs, propranolol, nadolol and metaraminol (I, III, IV). Incorporation of 
these positively charged molecules into Smopex-102 fiber decreased their permeation 
across the skin as compared to drug permeation from the corresponding solution 
formulations.  
 
In order to check the apparent limit of permeation rate, the iontophoretic permeation rate 
of tacrine across the skin was measured from fiber discs containing different amounts 
(17.6-104 mg) of drug (I). When the amount of tacrine in the fiber was increased, also the 
flux of tacrine across the skin was increased (I: Fig. 5). The increase was not linear in the 
whole concentration range considered. It has been presumed, that the concentration in the 
solution is proportional to the concentration within the fiber and, thus, this non-linearity 
cannot be due to the difference between the drug concentration in the solution and the 
concentration in the fiber. It is then concluded that the permeation across the skin shows a 
limiting mechanism at higher concentrations. This finding supports the observations 
reported of a similar drop off in the delivery rates of nicotine at high concentrations from 
a hydrogel containing ion-exchange resins across the skin (Conaghey et al., 1998b).  
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5.5 Drug permeation studies in vivo (I, III) 
 
5.5.1 Transdermal delivery of tacrine for systemic use (I) 
 
Based on the physico-chemical properties, the model drug tacrine is a promising 
candidate for transdermal delivery. During oral administration tacrine undergoes 
extensive first-pass metabolism and its dose-dependent hepatotoxicity and peripheral 
cholinenergic side effects have been observed (Wagstaff and McTavish, 1994). It has 
been postulated that maintenance of constant levels of tacrine in the brain may be 
required to maximize its effects on memory enhancement (Telting-Diaz and Lunte, 
1993). Transdermal delivery of tacrine may minimize the above-mentioned problems. 
Steady-state plasma concentrations after transdermal drug permeation can be calculated 
using Equation 4. For tacrine the CL = 150 l/h and the target plasma level after oral 
tacrine ingestion is 5–30 ng/ml (Wagstaff and McTavish, 1994). Using these parameters, 
the passive tacrine permeation from the 5 % solution would result in a plasma level of 
0.50 ng/ml and the ion-exchange reservoir will attenuate that level by three orders of 
magnitude. Thus, a need for permeation enhancement is obvious. Iontophoretic tacrine 
delivery from the 5 % solution should result in plasma levels of 4.3 ng/ml at 0.1 mA/cm2 
and 36 ng/ml at 0.5 mA/cm2 (I). Iontophoretic delivery from the ion-exchange fiber (0.5 
mA/cm2) is expected to yield 7.3 ng/ml of tacrine in plasma at steady state. Overall, 
therefore, it seemed that clinically relevant amounts of tacrine might be delivered 
transdermally by the ion-exchange fiber and iontophoresis, presuming that the 
permeation rates across the skin in vitro and in vivo are the same (I). 
 
5.5.2 Controlled transdermal delivery of tacrine in vivo (III) 
 
Drug delivery (III): The plasma concentrations of tacrine after drug delivery from the 
Iogel-formulation and from the ion-exchange fiber-formulation (Fig. 4) were 21.3 ± 5.9 
and 14.9 ± 2.6 ng/ml, respectively (Fig. 7). Plasma concentrations of tacrine were smaller 
by the use of ion-exchange fiber device than by the gel-electrode (p < 0.05). Both the ion-
exchange fiber and gel formulations achieved constant plasma concentrations of tacrine 
within 30 mins. During the one hour passive tacrine permeation (180-240 min), the 
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plasma concentrations of tacrine decreased only slightly (Fig. 7). This may be due to the 
formation of tacrine reservoir in the skin during the drug delivery. Tacrine is a rather 
lipophilic drug with a log Poct = 3.3, (Drayton, 1990), which may well be bound into the 
lipophilic skin structures (stratum corneum), and to be released slowly from there into the 
systemic circulation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Plasma concentrations of tacrine as a function of time. Test I, Iogel-
electrodes (N = 10) (♦) and Test II, ion-exchange fiber device (N = 9) (ٱ). 
Average ± SD. To distinguish the Tests I and II, the curve of the latter has been 
transferred for 5 min. 
 
In general, the inter- and intrasubject variations are high in human pharmacokinetic 
studies, and variability is a problem also in both the passive and iontophoretic 
transdermal drug delivery (Ashburn et al., 1995; van der Geest et al., 1997; Gupta et al., 
1998; Rohr et al., 1998). By the use of ion-exhange fiber this variation was attempted to 
be reduced, but at least in the case of tacrine, this was not achieved (III). The standard 
deviations during the iontophoresis in Test II were slightly smaller than using the gel 
system (Test I), but the difference was not statistically significant (p > 0.05). Subject 
0
10
20
30
40
50
60
0 30 60 90 120 150 180 210 240 270
Time (min)
Ta
cr
in
e 
pl
as
m
a 
co
nc
en
tra
tio
n 
(n
g/
m
l)
 44 
variations were, however, quite small in both the gel- and ion-exchange formulations. 
Even if the absorption kinetics of a drug may be controlled by the use of proper drug 
delivery system like transdermal patch, the clearence of the drug or the barrier function of 
the skin of the individual subjects can not be predetermined.  
 
Safety (III): In addition to poor permeability of drugs, adverse skin reactions, mainly 
skin irritation, limit the number of potential drug candidates for transdermal drug 
administration (Ledger, 1992). Enhancement of transdermal drug delivery, including the 
use of iontophoresis, may also lead to irritant reactions in the skin (Ashburn et al., 1995). 
Table 9 lists the adverse reactions on the skin by the visual observations and by the 
personal comments of the volunteers during the iontophoretic tacrine delivery Tests I and 
II (+ control data). One volunteer interrupted the Test II due to painful blood sampling 
(no relation to skin irritation). Application of tacrine solution (without iontophoresis) on 
the skin did not result in any visible/sensitization reactions. In contrast, the skin of all the 
study subjects was clearly erythematous by the iontophoretic current delivery (Table 9). 
The irritation of the skin was directly related to the iontophoretic current density (0.1-0.4 
mA/cm2) and the duration of application. The subjects that had a light skin reported a 
stronger and longer lasting erythema. It’s to be noted, that after hard physical activity the 
skin of five volunteers was little erythematous even one week after the experiment. 
Slightly pinching sensation was felt by all the study subjects at the first minutes of 
current passage at the sites of application and at nearby regions. A sensation was felt 
every time the current density was increased or the position of the device was changed.  
 
Although tacrine itself did not increase the erythema at the concentration used, drying of 
the skin was observed on several study subjects (Table 9). Tacrine, an anticholinergic 
drug, caused also sensations of coldness on the skin and on the fingertips of 50 % of the 
study subjects. Transdermal delivery of tacrine had no effect on the alanine 
aminotransferase levels of the volunteers in these short tests. All the ALT-values of the 
test subjects stayed under the normal range (≤ 50 U/l). Obviously, further trials are 
needed to determine the possible effects of long-term transdermal delivery of tacrine on 
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the liver function. Liver toxicity of tacrine is expected to be lower transdermally than by 
oral administration due to the decreased first-pass metabolism.   
 
Table 9. Adverse side effects following transdermal iontophoresis of tacrine. 
Number of volunteers in Test I = 10 and II = 9. Control measurements (N = 5) 
included tacrine in solution (no iontophoresis) or iontophoretic current (no 
tacrine). 
 
Adverse effect           Test I        Test II        Tacrine        Iontophoresis 
 
Pinching   10     9  0  5 
Erythema     7     7  0  3 
Strong erythema    3     2  0  2 
Drying of the skin  5     5  1  2 
Coldness on the skin  5     5  0  0 
and fingertips 
 
 
 
The observed side effects caused by the iontophoresis in these experiments did not differ 
significantly from the side effects observed previously (Ashburn et al., 1995; van der 
Geest et al., 1997; Gupta et al., 1998). Because all the plasma concentrations determined 
were higher than the smallest therapeutic tacrine concentration, a lower or intermittent 
current density may be used and still reach clinically relevant medication transdermally. 
In addition, when the transdermal system is attached into a new site, iontophoresis has to 
create new ”pores” to the stratum corneum and this causes temporary lag time and 
reduction in the drug flux. For this reason, tacrine concentrations would possibly have 
been even higher, if the system would have stayed at the same location for the whole 
experiment. 
 
In vitro/in vivo correlation of tacrine permeation (III): Tacrine was delivered from the 
gel (Test I) and from the ion-exchange fiber (Test II) for 3 h by iontophoresis and for 1 h 
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passively in vitro. At the beginning there was a short lag time (30 min) in the tacrine flux. 
Thereafter, the flux was constant until the current was turned off. After current 
termination the in vitro transdermal tacrine flux returned rapidly to a passive level. Thus, 
in contrast to tacrine delivery in vivo, the drug flux across the human skin in vitro 
decreased dramatically when the current was turned off. The reason for this may lie in the 
preferable partitioning of tacrine in the skin structures, which prevents it from entering 
the hydrophilic receptor chamber (no general circulation to distribute the drug throughout 
the individual subject). The flux values for the tacrine permeation were 5.61 ± 1.31 
µg/min per cm2 (gel-formulation) and 0.11 ± 0.049 µg/min per cm2 (ion-exchange-fiber 
formulation). Based on these flux values, the predicted in vivo plasma levels would be 
22.4 ± 5.3 ng/ml and 0.43 ± 0.19 ng/ml using the gel and the ion-exchange formulations, 
respectively. The corresponding in vivo data values were 21.3 ± 5.9 ng/ml and 14.9 ± 2.6 
ng/ml. The correlation between the in vitro and in vivo data was very good in the case of 
gel formulation. However, with the ion-exchange fiber formulation, the in vitro data 
predicts a significantly smaller flux than the actual drug delivery in vivo was.  
 
Other research groups have observed variable results on transdermal in vitro/in vivo 
correlation (Franz, 1975; Franz, 1978; Guy et al., 1986; Riviere et al., 1990; Riviere et 
al., 1991; Green et al., 1992; Phipps and Gyory, 1992; van der Geest et al., 1997; Fang et 
al., 1999; Magnusson et al., 2000). E.g., Phipps and Gyory (1992) observed that the drug 
concentration in iontophoretic drug delivery in vivo was generally higher than the 
concentration in vitro, while van der Geest at al. (1997) observed contradictional results, 
in vitro permeation of apomorphine was greater than the in vivo delivery. The correlation 
seems to be, therefore, highly dependent on the experimental conditions, the individual 
skin source, and the drug in question. To find out the reason(s) for the poor correlation 
between the in vivo and in vitro studies involving the ion-exchange fiber formulation 
(Test II), further studies are needed.  
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6 CONCLUSIONS 
 
This study focused on controlled transdermal drug delivery. Iontophoresis and cation- 
and anion-exchange fibers were used to control the drug adsorption/release and the 
kinetics of drug permeation. The main conclusions are: 
 
1) Cation- and anion-exchange fibers have been shown to be promising drug reservoir 
materials for iontophoretic transdermal delivery devices. 
 
2) The release rate of drugs from the ion-exchange fibers depends on a specific 
combination of the drug, fiber, and the concentration and nature of the external 
electrolyte. 
 
3) Ion-exchange fibers are promising materials also for the storage of easily degradable 
and oxidizable drugs. 
 
4) Iontophoresis and ion-exchange fibers provide a potential mean to precisely control 
the permeation of drugs across the skin (stratum corneum). 
 
5) Clinically relevant plasma concentrations of tacrine were reached in human 
volunteers by transdermal iontophoresis (gel-formulation, ion-exchange fiber 
formulation). Only minor irritation on the skin was observed, which was caused 
mainly by the iontophoretic current delivery. 
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